Information  X 
Enter a valid email address

C4X Discovery (C4XD)

  Print      Mail a friend

Tuesday 16 October, 2018

C4X Discovery

Grant of Options and Director Dealing

RNS Number : 1853E
C4X Discovery Holdings PLC
16 October 2018
 

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR IN ANY OTHER JURISDICTION IN WHICH OFFERS, OR SALES WOULD BE PROHIBITED BY APPLICABLE LAW. THIS ANNOUNCEMENT IS NOT AN OFFER TO SELL OR A SOLICITATION TO BUY SECURITIES IN ANY JURISDICTION, INCLUDING THE UNITED STATES, CANADA, AUSTRALIA, JAPAN AND THE REPUBLIC OF SOUTH AFRICA. NEITHER THIS ANNOUNCEMENT NOR ANYTHING CONTAINED HEREIN SHALL FORM THE BASIS OF, OR BE RELIED UPON IN CONNECTION WITH, ANY OFFER OR COMMITMENT WHATSOEVER IN ANY JURISDICTION.

 

C4X Discovery Holdings plc

("C4XD" or the "Company")

 

GRANT OF OPTIONS AND DIRECTORS DEALING

 

16 October 2018 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering drug discovery company, announces today that a total of 150,000 options over ordinary shares of the Company were awarded pursuant to the EMI 2014 Plan to certain employees, which includes 50,000 options each to Dr Clive Dix, Chief Executive Officer, Dr Craig Fox, Chief Scientific Officer and Brad Hoy, Chief Financial Officer, as set out below.

 

Director

Position

Number of share options awarded

Option exercise price per share (pence)

Total number of options held

Dr Clive Dix

Chief Executive Officer

50,000

89.2

195,000

Dr Craig Fox

Chief Scientific Officer        

50,000

89.2

250,000

Brad Hoy

Chief Financial Officer                                   

50,000

89.2

350,000

 

The options have an exercise price of 89.2p, being the average 30-day closing price of the Ordinary Shares to the 12 October 2018. The options can be exercised at any time between 3 years and 10 years of them being granted.

 

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name(s)

 

Dr Clive Dix

2

Reason for the notification


a)


Position/status

 

Chief Executive Officer, Director

b)

Initial notification/Amendment

 

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

C4X Discovery Holdings plc

b)

LEI

213800UHNL82E323O870

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code
 

Options over 1p Ordinary Shares - EMI 2014 Plan

 

 

ISIN GB00BQQ2RV18

b)

Nature of the transaction

 

Grant of Options over Ordinary Shares

c)

Price(s) and volume(s)

 

 

Price(s)

Volume(s)

89.2p

50,000

 

d)

Aggregated information

 

 

e)

Date of the transaction

 

15 October 2018

f)

Place of the transaction

 

 

London Stock Exchange - AIM

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

 

Dr Craig Fox

2

Reason for the notification


a)


Position/status

 

Chief Scientific Officer, Director

b)

Initial notification/Amendment

 

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

C4X Discovery Holdings plc

b)

LEI

213800UHNL82E323O870

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code
 

Options over 1p Ordinary Shares - EMI 2014 Plan

 

 

ISIN GB00BQQ2RV18

b)

Nature of the transaction

 

Grant of Options over Ordinary Shares

c)

Price(s) and volume(s)

 

 

Price(s)

Volume(s)

89.2p

50,000

 

d)

Aggregated information

 

 

e)

Date of the transaction

 

15 October 2018

f)

Place of the transaction

 

 

London Stock Exchange - AIM

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

 

Brad Hoy

2

Reason for the notification


a)


Position/status

 

Chief Financial Officer, Director

b)

Initial notification/Amendment

 

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

C4X Discovery Holdings plc

b)

LEI

213800UHNL82E323O870

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code
 

Options over 1p Ordinary Shares - EMI 2014 Plan

 

 

ISIN GB00BQQ2RV18

b)

Nature of the transaction

 

Grant of Options over Ordinary Shares

c)

Price(s) and volume(s)

 

 

Price(s)

Volume(s)

89.2p

50,000

 

d)

Aggregated information

 

 

e)

Date of the transaction

 

15 October 2018

f)

Place of the transaction

 

 

London Stock Exchange - AIM

 

--ENDS-

 

For further information, please contact:

C4X Discovery Holdings plc

Clive Dix, Chief Executive Officer                                                                                                       07801 865 803

 

Panmure Gordon (UK) Limited (NOMAD)                                                                                      020 7886 2500

Freddy Crossley, Emma Earl (Corporate Finance)                                                                                             

James Stearns (Corporate Broking)                                                                                                                        

 

Consilium Strategic Communications                                                                                              020 3709 5700

Mary-Jane Elliott, Matthew Neal, Chris Gardner                                                                                                        

 

About C4X Discovery

 

C4X Discovery aims to become the world's most productive drug discovery engine by exploiting cutting edge technologies to design and create best-in-class small-molecule candidates targeting a range of high value therapeutic areas. The company's goal is to drive returns through early-stage revenue-generating deals with the pharmaceutical industry.

 

C4X Discovery has a state-of-the-art suite of proprietary technologies across the drug discovery process. The company's innovative DNA-based target identification platform (Taxonomy3®) utilises human genetic datasets to identify novel patient-specific targets leading to greater discovery productivity and increased probability of clinical success. This is complemented by C4XD's novel drug design platform which comprises two innovative chemistry technologies, Conformetrix and Molplex, that combine 4D molecular shape analyses (based on experimental data) with best-in-class computational chemistry. This provides new and unprecedented insight into the behaviour of drug molecules, enabling the production of potent selective compounds faster and more cost effectively than the industry standard.

 

C4X Discovery is advancing its in-house pipeline that is primarily focused on the high value therapeutic areas of inflammation, neurodegeneration and cancer (including immuno-oncology) with a number of new drug candidates identified and further progress made towards pre-clinical licensing discussions. In selecting and executing new drug discovery programmes, C4X Discovery focuses on high-value disease areas that are the subject of significant licensing activity and will continue to also maximise value from opportunistic areas such as addiction and diabetes. The Company recently signed a licensing agreement with Indivior for a pre-clinical addiction programme worth up to $294 million.

 

The Company was founded as a spin-out from the University of Manchester. It has a highly experienced management team and Board who have delivered significant value creation within the healthcare sector historically and have enabled C4XD to reach multiple value inflexion points since IPO. For additional information please go to: www.c4xdiscovery.com

 

 

--ENDS----

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
DSHUNSWRWUARARA

a d v e r t i s e m e n t